Addison Advisors LLC Acquires 255 Shares of Novo Nordisk A/S (NYSE:NVO)

Addison Advisors LLC raised its holdings in Novo Nordisk A/S (NYSE:NVO) by 12.3% during the fourth quarter, Holdings Channel.com reports. The fund owned 2,331 shares of the company’s stock after purchasing an additional 255 shares during the period. Addison Advisors LLC’s holdings in Novo Nordisk A/S were worth $241,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Headlands Technologies LLC boosted its stake in Novo Nordisk A/S by 33.1% in the fourth quarter. Headlands Technologies LLC now owns 2,857 shares of the company’s stock valued at $296,000 after acquiring an additional 711 shares during the last quarter. Citizens Financial Group Inc. RI boosted its stake in Novo Nordisk A/S by 1.8% in the fourth quarter. Citizens Financial Group Inc. RI now owns 13,703 shares of the company’s stock valued at $1,418,000 after acquiring an additional 239 shares during the last quarter. Truist Financial Corp boosted its stake in Novo Nordisk A/S by 1.6% in the fourth quarter. Truist Financial Corp now owns 597,059 shares of the company’s stock valued at $61,766,000 after acquiring an additional 9,450 shares during the last quarter. Callan Capital LLC boosted its stake in Novo Nordisk A/S by 260.8% in the fourth quarter. Callan Capital LLC now owns 21,259 shares of the company’s stock valued at $2,199,000 after acquiring an additional 15,366 shares during the last quarter. Finally, Herold Advisors Inc. boosted its stake in Novo Nordisk A/S by 108.3% in the fourth quarter. Herold Advisors Inc. now owns 5,000 shares of the company’s stock valued at $517,000 after acquiring an additional 2,600 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on NVO. UBS Group began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They issued a “neutral” rating on the stock. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Morgan Stanley began coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price on the stock. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Up 0.8 %

Shares of NYSE:NVO traded up $1.06 during midday trading on Friday, reaching $126.85. 3,312,457 shares of the company were exchanged, compared to its average volume of 3,307,405. Novo Nordisk A/S has a fifty-two week low of $75.56 and a fifty-two week high of $138.28. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The stock has a fifty day simple moving average of $126.86 and a two-hundred day simple moving average of $111.98. The firm has a market cap of $569.24 billion, a PE ratio of 46.90, a P/E/G ratio of 2.10 and a beta of 0.41.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, topping analysts’ consensus estimates of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion for the quarter, compared to analyst estimates of $9.14 billion. As a group, sell-side analysts forecast that Novo Nordisk A/S will post 3.32 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Investors of record on Monday, March 25th were issued a dividend of $0.664 per share. This represents a dividend yield of 0.9%. This is a positive change from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. The ex-dividend date was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.